Jim Lambert PhD

Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer.  Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology.